New Leaf Venture Partners Affirms Its Support of Roumell Asset Management’s Letter to Transcept Pharmaceuticals’ Board New York, NY September 9, 2013 – New Leaf Venture Partners (NLV Partners) announced that the Company has submitted today a letter to the Board...
Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219 – Study Showed AF-219 Reduced Daytime Cough Frequency by 75% in Patients with Treatment-Refractory Chronic Cough – New Findings Featured in...
First Patient Enrolls in U.S. Salus Trial Evaluating Direct Flow Medical® Transcatheter Aortic Heart Valve System SANTA ROSA, Calif., September 10, 2013 – Direct Flow Medical®, Inc., a transcatheter heart valve company focused on improving patient outcomes,...
Durata Therapeutics Presents New Pivotal Phase 3 Clinical Results and New In Vitro Data on Dalbavancin at ICAAC DENVER, Sept. 10, 2013 (GLOBE NEWSWIRE) — Durata Therapeutics, Inc. (Nasdaq:DRTX) today presented clinical trial results from its two Phase 3 DISCOVER...
New Treato Pharma Release Brings Real-time “Patient Voice” Intelligence into the Executive Suite YEHUD, Israel, September 10, 2013 – Treato, the source of “patient voice” intelligence from across the social web, today announced the new version...
Recent Comments